BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20164240)

  • 41. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
    Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
    Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
    Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway.
    Miao H; Wei BR; Peehl DM; Li Q; Alexandrou T; Schelling JR; Rhim JS; Sedor JR; Burnett E; Wang B
    Nat Cell Biol; 2001 May; 3(5):527-30. PubMed ID: 11331884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.
    Tamborini E; Bonadiman L; Greco A; Gronchi A; Riva C; Bertulli R; Casali PG; Pierotti MA; Pilotti S
    Clin Cancer Res; 2004 Feb; 10(3):938-43. PubMed ID: 14871970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma.
    Ueno S; Sudo T; Oka N; Wakahashi S; Yamaguchi S; Fujiwara K; Mikami Y; Nishimura R
    Int J Gynecol Cancer; 2013 Jul; 23(6):1084-91. PubMed ID: 23792604
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.
    Xu KP; Yin J; Yu FS
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2832-9. PubMed ID: 16799022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
    Lee DH; Zhang Y; Kassam AB; Park MJ; Gardner P; Prevedello D; Henry S; Horbinski C; Beumer JH; Tawbi H; Williams BJ; Shaffrey ME; Egorin MJ; Abounader R; Park DM
    PLoS One; 2015; 10(8):e0134426. PubMed ID: 26247786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.
    Porter AC; Vaillancourt RR
    Oncogene; 1998 Sep; 17(11 Reviews):1343-52. PubMed ID: 9779982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Receptor association and tyrosine phosphorylation of S6 kinases.
    Rebholz H; Panasyuk G; Fenton T; Nemazanyy I; Valovka T; Flajolet M; Ronnstrand L; Stephens L; West A; Gout IT
    FEBS J; 2006 May; 273(9):2023-36. PubMed ID: 16640565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
    Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
    Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
    Sano A; Sakurai S; Kato H; Suzuki S; Yokobori T; Sakai M; Tanaka N; Inose T; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Ojima H; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Kuwano H
    Oncol Rep; 2013 Jun; 29(6):2119-26. PubMed ID: 23546020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of platelet-derived growth factor receptor in eotaxin signaling of eosinophils.
    Adachi T; Hanaka S; Yano T; Yamamura K; Yoshihara H; Nagase H; Chihara J; Ohta K
    Int Arch Allergy Immunol; 2006; 140 Suppl 1():28-34. PubMed ID: 16772724
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Luteinizing hormone signaling in preovulatory follicles involves early activation of the epidermal growth factor receptor pathway.
    Panigone S; Hsieh M; Fu M; Persani L; Conti M
    Mol Endocrinol; 2008 Apr; 22(4):924-36. PubMed ID: 18187604
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RAS/MAPK pathway hyperactivation determines poor prognosis in undifferentiated pleomorphic sarcomas.
    Serrano C; Romagosa C; Hernández-Losa J; Simonetti S; Valverde C; Moliné T; Somoza R; Pérez M; Vélez R; Vergés R; Domínguez R; Carles J; Ramón Y Cajal S
    Cancer; 2016 Jan; 122(1):99-107. PubMed ID: 26479291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.